<html xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type  content="text/html; charset=UTF-8" ><meta name=ProgId  content=Word.Document ><meta name=Generator  content="Microsoft Word 14" ><meta name=Originator  content="Microsoft Word 14" ><link rel=File-List  href="2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/filelist.xml" ><title></title><!--[if gte mso 9]><xml><o:DocumentProperties><o:Author>DAVE</o:Author><o:LastAuthor>独自1388757202</o:LastAuthor><o:Revision>1</o:Revision><o:Pages>10</o:Pages><o:Characters>28956</o:Characters><o:Lines>222</o:Lines><o:Paragraphs>62</o:Paragraphs></o:DocumentProperties><o:CustomDocumentProperties><o:KSOProductBuildVer dt:dt="string" >2052-12.1.0.18608</o:KSOProductBuildVer><o:ICV dt:dt="string" >4B7A1CA754254494A4CEC49D93D1817E_13</o:ICV><o:KSORubyTemplateID dt:dt="string" >6</o:KSORubyTemplateID></o:CustomDocumentProperties></xml><![endif]--><!--[if gte mso 9]><xml><o:OfficeDocumentSettings></o:OfficeDocumentSettings></xml><![endif]--><!--[if gte mso 9]><xml><w:WordDocument><w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel><w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery><w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery><w:DocumentKind>DocumentNotSpecified</w:DocumentKind><w:DrawingGridVerticalSpacing>7.8 磅</w:DrawingGridVerticalSpacing><w:PunctuationKerning></w:PunctuationKerning><w:View>Web</w:View><w:Compatibility><w:AdjustLineHeightInTable/><w:DontGrowAutofit/><w:BalanceSingleByteDoubleByteWidth/><w:DoNotExpandShiftReturn/><w:UseFELayout/></w:Compatibility><w:Zoom>0</w:Zoom></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml><w:LatentStyles DefLockedState="false"  DefUnhideWhenUsed="true"  DefSemiHidden="true"  DefQFormat="false"  DefPriority="99"  LatentStyleCount="260" >
<w:LsdException Locked="false"  Priority="0"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Normal" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="heading 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="9"  SemiHidden="false"  QFormat="true"  Name="heading 9" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index 9" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  Name="toc 9" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Normal Indent" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="footnote text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="annotation text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="header" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="footer" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="index heading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="35"  SemiHidden="false"  QFormat="true"  Name="caption" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="table of figures" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="envelope address" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="envelope return" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="footnote reference" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="annotation reference" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="line number" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="page number" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="endnote reference" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="endnote text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="table of authorities" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="macro" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="toa heading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Bullet 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Number 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="10"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Title" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Closing" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Signature" ></w:LsdException>
<w:LsdException Locked="false"  Priority="1"  SemiHidden="false"  Name="Default Paragraph Font" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text Indent" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="List Continue 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Message Header" ></w:LsdException>
<w:LsdException Locked="false"  Priority="11"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Subtitle" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Salutation" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Date" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text First Indent" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text First Indent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Note Heading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text Indent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Body Text Indent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Block Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="Hyperlink" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="FollowedHyperlink" ></w:LsdException>
<w:LsdException Locked="false"  Priority="22"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Strong" ></w:LsdException>
<w:LsdException Locked="false"  Priority="20"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="Emphasis" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Document Map" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Plain Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="E-mail Signature" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Normal (Web)" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Acronym" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Address" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Cite" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Code" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Definition" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Keyboard" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Preformatted" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Sample" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Typewriter" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="HTML Variable" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Normal Table" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="annotation subject" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="No List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="1 / a / i" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="1 / 1.1 / 1.1.1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Article / Section" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Simple 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Simple 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Simple 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Classic 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Colorful 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Colorful 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Colorful 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Columns 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Grid 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 7" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table List 8" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table 3D effects 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table 3D effects 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table 3D effects 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Contemporary" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Elegant" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Professional" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Subtle 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Subtle 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Web 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Web 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Web 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  QFormat="true"  Name="Balloon Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="39"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Table Grid" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Table Theme" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Placeholder Text" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="No Spacing" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  UnhideWhenUsed="false"  QFormat="true"  Name="List Paragraph" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Quote" ></w:LsdException>
<w:LsdException Locked="false"  Priority="99"  SemiHidden="false"  Name="Intense Quote" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 1" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 2" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 3" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 4" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 5" ></w:LsdException>
<w:LsdException Locked="false"  Priority="60"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Shading Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="61"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light List Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="62"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Light Grid Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="63"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 1 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="64"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Shading 2 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="65"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 1 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="66"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium List 2 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="67"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 1 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="68"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 2 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="69"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Medium Grid 3 Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="70"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Dark List Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="71"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Shading Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="72"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful List Accent 6" ></w:LsdException>
<w:LsdException Locked="false"  Priority="73"  SemiHidden="false"  UnhideWhenUsed="false"  Name="Colorful Grid Accent 6" ></w:LsdException>
</w:LatentStyles></xml><![endif]--><style>
@font-face{
font-family:"Times New Roman";
}

@font-face{
font-family:"宋体";
}

@font-face{
font-family:"等线";
}

@font-face{
font-family:"Wingdings";
}

@font-face{
font-family:"Arial Narrow";
}

@font-face{
font-family:"微软雅黑";
}

p.MsoNormal{
mso-style-name:正文;
mso-style-parent:"";
margin:0pt;
margin-bottom:.0001pt;
mso-pagination:none;
text-align:justify;
text-justify:inter-ideograph;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

span.10{
font-family:'Times New Roman';
}

span.15{
font-family:'Times New Roman';
font-size:9.0000pt;
mso-font-kerning:1.0000pt;
}

span.16{
font-family:'Times New Roman';
color:rgb(5,99,193);
text-decoration:underline;
text-underline:single;
}

span.17{
font-family:'Times New Roman';
font-size:10.5000pt;
}

span.18{
font-family:'Times New Roman';
font-size:9.0000pt;
}

span.19{
font-family:'Times New Roman';
font-size:9.0000pt;
}

span.20{
font-family:'Times New Roman';
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

span.21{
font-family:'Times New Roman';
font-weight:bold;
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

p.MsoCommentText{
mso-style-name:批注文字;
mso-style-noshow:yes;
margin:0pt;
margin-bottom:.0001pt;
mso-pagination:none;
text-align:left;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

p.MsoAcetate{
mso-style-name:批注框文本;
mso-style-noshow:yes;
margin:0pt;
margin-bottom:.0001pt;
mso-pagination:none;
text-align:justify;
text-justify:inter-ideograph;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;
mso-font-kerning:1.0000pt;
}

p.MsoCommentSubject{
mso-style-name:批注主题;
mso-style-noshow:yes;
mso-style-parent:批注文字;
mso-style-next:批注文字;
margin:0pt;
margin-bottom:.0001pt;
mso-pagination:none;
text-align:left;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-weight:bold;
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

p.MsoFooter{
mso-style-name:页脚;
mso-style-noshow:yes;
margin:0pt;
margin-bottom:.0001pt;
layout-grid-mode:char;
mso-pagination:none;
text-align:left;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;
mso-font-kerning:1.0000pt;
}

p.MsoHeader{
mso-style-name:页眉;
mso-style-noshow:yes;
margin:0pt;
margin-bottom:.0001pt;
border-bottom:1.0000pt solid windowtext;
mso-border-bottom-alt:0.7500pt solid windowtext;
padding:0pt 0pt 1pt 0pt ;
layout-grid-mode:char;
mso-pagination:none;
text-align:center;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;
mso-font-kerning:1.0000pt;
}

p.27{
mso-style-name:"List Paragraph";
margin:0pt;
margin-bottom:.0001pt;
text-indent:21.0000pt;
mso-char-indent-count:2.0000;
mso-pagination:none;
text-align:justify;
text-justify:inter-ideograph;
font-family:等线;
mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;
mso-font-kerning:1.0000pt;
}

span.msoIns{
mso-style-type:export-only;
mso-style-name:"";
text-decoration:underline;
text-underline:single;
color:blue;
}

span.msoDel{
mso-style-type:export-only;
mso-style-name:"";
text-decoration:line-through;
color:red;
}

table.MsoNormalTable{
mso-style-name:普通表格;
mso-style-parent:"";
mso-style-noshow:yes;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-padding-alt:0.0000pt 5.4000pt 0.0000pt 5.4000pt;
mso-para-margin:0pt;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-family:'Times New Roman';
font-size:10.0000pt;
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;
}
@page{mso-page-border-surround-header:no;
	mso-page-border-surround-footer:no;}@page Section0{
margin-top:72.0000pt;
margin-bottom:72.0000pt;
margin-left:90.0000pt;
margin-right:90.0000pt;
size:595.3000pt 841.9000pt;
layout-grid:15.6000pt;
mso-header-margin:42.5500pt;
mso-footer-margin:49.6000pt;
mso-page-numbers:num-in-dash;
mso-title-page:yes;
mso-header:url("2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/header.html") h0;
mso-footer:url("2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/header.html") f0;
mso-first-header:url("2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/header.html") fh0;
mso-first-footer:url("2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/header.html") ff0;
}
div.Section0{page:Section0;}@page Section1{
margin-top:72.0000pt;
margin-bottom:72.0000pt;
margin-left:90.0000pt;
margin-right:90.0000pt;
size:595.3000pt 841.9000pt;
layout-grid:15.6000pt;
mso-header-margin:42.5500pt;
mso-footer-margin:49.6000pt;
mso-page-numbers:num-in-dash;
mso-header:url("2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/header.html") h1;
mso-footer:url("2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/header.html") f1;
mso-first-header:url("2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/header.html") fh1;
mso-first-footer:url("2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/header.html") ff1;
}
div.Section1{page:Section1;}</style></head><body style="tab-interval:21pt;text-justify-trim:punctuation;" ><!--StartFragment--><div class="Section0"  style="layout-grid:15.6000pt;" ><p class=MsoNormal  align=center  style="text-align:center;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:18.0000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >消癖颗粒通过抑制肿瘤</font><font face="等线" >T</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:18.0000pt;mso-font-kerning:1.0000pt;" >AM</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:18.0000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >s</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:18.0000pt;mso-font-kerning:1.0000pt;" >/CXCL1通路抑制乳腺癌干细胞</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:18.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  align=center  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;text-align:center;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >王胜奇</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >1，2，3</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，刘晓雁</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >1</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，黄仁伦</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >1</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >，</font><font face="宋体" >2</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，郑轶枫</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >1</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >，</font><font face="宋体" >2，3</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，王能</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >1，4</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，杨博文</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >1</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >，</font><font face="宋体" >2</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，司徒红林</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >1</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，林毅</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >1</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，王志宇</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >1，2，3，4</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=27  align=center  style="text-indent:24.0000pt;text-align:center;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >DOI </span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
color:rgb(0,0,0);font-size:10.5000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span><a href="https://doi.org/10.3389/fphar.2019.01371" ><u><span class="16"  style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
color:rgb(0,0,0);text-decoration:underline;text-underline:single;
font-size:12.0000pt;" >https://doi.org/10.3389/fphar.2019.01371</span></u></a></span><u><span class="16"  style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
color:rgb(0,0,0);text-decoration:underline;text-underline:single;
font-size:12.0000pt;" ><o:p></o:p></span></u></p><p class=27  align=center  style="text-indent:24.0000pt;text-align:center;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Frontiers in Pharmacology ( IF 5.810 )</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >摘要</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在包括乳腺癌在内的多种恶性肿瘤中，巨噬细胞是与宿主免疫系统相关最密切的基质细胞。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2018年，消</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(XPS)经国家食品药品监督管理局(SFDA)批准用于治疗乳腺增生症，临床疗效确切，无明显不良反应。现有关于XPS抗乳腺癌活性及其作用机制的研究非常有限。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >本研究旨在探讨</font>XPS能否通过调节肿瘤相关巨噬细胞在肿瘤微环境中发挥抗乳腺癌作用。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在此，我们利用</font>transwell共培养系统将乳腺癌细胞与TAMs共同培养，模拟它们共存的情况。在共培</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >养体系中，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS能显著抑制人和小鼠乳腺癌细胞的增殖、集落形成、乳腺癌干细胞亚群、乳腺微球形成能力以及干细胞相关基因的表达。此外，XPS还能抑制M2表型极化，抑制CXCL1的表达和分泌。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >值得注意的是，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >进一步的机制研究证实，</font>TAMs/CXCL1是XPS在共培养体</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >系中</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >抑制乳腺</font>CSCs自我更新的关键靶点，因为外源性CXCL1可以</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >抵消</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS对乳腺CSCs自我更新的抑制作用。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >更重要的是</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在小鼠</font><font face="宋体" >4</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >T1</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >-</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >L</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >uc异种移植体内</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >能显著抑制乳腺肿瘤生长、乳腺</font>CSCs亚群和TAMs/CXCL1的活性，而且没有</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >任何可检测到的副作用。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >综上所述，本研究不仅揭示了</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS在乳腺癌治疗中的免疫调节机制，而且为TAMs/CXCL1作为消除</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺</font><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >SC</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的潜在分子靶点提供了新的见解。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p>&nbsp;</o:p></span></b></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >引言</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌是最常见的恶性肿瘤，也是女性癌症相关死亡的第二大原因</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Allemani</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2015;Bray</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >1-2</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。乳腺癌本身约占全球新诊断癌症病例的</font>24.2%，占全球女性癌症相关死亡病例的15.0%(Bray等人，2018年)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >2】</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌的发病率仍在上升</font>(Allemani</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2015)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >1</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，全球乳腺癌发病年龄趋于年轻化</font>(Ali</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2011)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >3</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >虽然在过去几十年中，由于早期发现和包括常规手术、放射治疗、化疗、内分泌治疗和分子靶向治疗在内的多学科进展，乳腺癌患</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >者的总体存活率有了显著提高，但仍有相当比例的患者会复发，甚至死于乳腺癌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Chia等人，2008年)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >4</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。因此，人们正在作出广泛的努力，以确定新的治疗目标或开发新的药物治疗这</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >种</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >可怕的疾病。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中医药在延长癌症患者的生存时间、减轻副作用和提高生活质量方面取得了令人鼓舞的效果，几千年来，中医药一直被广泛应用于癌症的预防和治疗，主要在中国及其周边地区</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >Nie</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人，</font>2016;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >Liao</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人，</font>2017)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >5-6】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。值得注意的是，中医药在乳腺癌治疗中具有独特的优势，可以提高</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳房切除术后</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >短期治疗效果，延长</font>5年生存期，并减少乳腺癌患者乳腺切除术后的不良反应发生率(Tian等，2015;Wang等，2015)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >7</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >-8</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。中医药已广泛应用于乳腺癌的临床治疗。据估计，在台湾，超过</font>35.6%的乳腺癌患者曾接受过中医治疗(Lin and Chiu，2011)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >9</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >是</font>2018年12月28日国家食品药品监督管理局批准的新型抗乳腺增生药物。它已经在临床上用于治疗乳腺增生病几十年了，其疗效已被广泛的临床实践所证实。乳腺癌通常起源于不受控制的乳腺上皮细胞增生和乳腺导管增生，而</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >非典型增生则是乳腺的癌前病变</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Santisteban</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >., 2010)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >0</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。此外，网络药理学分析表明，消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中的</font>10种中药可能含有105种活性化合物，并进一步调控806个潜在靶点，其中81种与乳腺癌的发展密切相关(Wang等，2017)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >11</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。基于上述证据，我们推测</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒在</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >抑制乳腺癌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >方面</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >也</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >可能是</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >有效的。然而，现有关于</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >抗乳腺癌活性及其作用机制的研究非常有限。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在中医哲学中，乳腺癌被认为是一种系统性疾病，是细胞微环境失调的结果。因此，中医专注于内在免疫的整体增强和重塑肿瘤免疫微环境以治疗乳腺癌，而不是直接杀死癌细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Cohen等人，2002;Xie等人，2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >12-13</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。乳腺</font>CSCs是肿瘤细胞的一个亚</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >组</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，它们具有启动肿瘤的能力，自我更新的能力，多能性和高致</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >瘤性</font>(Vahidian等人，2019)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >4</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。越来越多的证据表明，乳腺</font>CSCs对乳腺癌的发</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >生</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、进展、复发和治疗耐药性至关重要</font>(Shima</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2017)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >5</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。因此，迫切需要采取更有针对性的策略来</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >针对</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌干细胞，以改善乳腺癌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >患者的预后。越来越多的证据表明，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CSCs可以通过</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >募集各种</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >免疫细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >并与之</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >相互作用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >来</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >逃避免疫破坏，促进免疫抑制</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >性</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >肿瘤微环境的建立</font>(Vahidian等人，2019)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >4</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >因此，进一步阐明乳腺</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CSC</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >与免疫细胞的相互作用和潜在的信号机制</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >将为改善乳腺癌免疫治疗提供新的机会</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Vahidian等人，2019)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >1</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >4</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >肿瘤免疫微环境由多种免疫细胞组成，包括巨噬细胞、自然杀伤细胞、骨髓源性抑制细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(MDSC)、调节性T细胞</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Tregs）、细胞毒性T淋巴细胞</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CTLs）和辅助性T细胞(Th)(Binnewies等人，2018年）</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >16</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。巨噬细胞是包括乳腺癌在内的多种恶性肿瘤中最丰富的免疫细胞</font>(Lao等人，2017;DelaFuenteLopez等人，2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >17-18</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。巨噬细胞一般分为两</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个广泛</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >但不同的亚类，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >即</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >经典激活</font>(M1)，或者是交替激活(M2或肿瘤相关的巨噬细胞(TAMs))(Parisi等人，2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >19</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font>M2型巨噬细胞在人类肿瘤中占主导地位，并产</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >生促生长趋化因子，促进肿瘤生长。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >TAMs的浸润创造了一种支持癌症发生和分泌多种细胞因子</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >促进癌症血管生成和侵袭</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >并抑制抗肿瘤免疫的炎症状态</font>(Mills</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >20</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font>TAMs也与促进乳腺癌的生长和转移有关(Hollmen</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >21</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。临床证据</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >有力</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >地证明了乳腺癌患者高</font>TAMs浸润与预后不良之间的关系(Tang</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2013;Hollmen等人，2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >21-22</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中医药因其在肿瘤治疗中的重要作用而倍受关注。多项研究表明，抑制</font>TAMs向M2型极化或重编程TAMs向M1型转变可以抑制肿瘤生长(Parisi等人，2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >19</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。然而，</font>XPS能否抑制肿瘤免疫微环境中巨噬细胞M2极化或其细胞因子的分泌，目前尚不清楚</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >本研究通过体外构建</font><font face="宋体" >T</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >AM</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s与乳腺癌细胞共培养体系和体内构建乳腺癌细胞异种移植物，系统地证明</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS能够抑制M2表型极化以及CXCL1的表达和分泌，最终导致</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对乳腺癌细胞自我更新的抑制作用。总的来说，我们的研究揭示了</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在乳腺癌治疗中的免疫调节机制，并强调</font>TAMs/CXCL1是一个潜在的分子靶点，可用于消除乳腺CSCs。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p></div>
<span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><br clear=all style='page-break-before:always;mso-break-type:section-break'></span>
<div class="Section1"  style="layout-grid:15.6000pt;" ><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >物料及方法</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >细胞培养和诱导</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >来自于美国菌种保藏中心的非恶性人乳腺上皮细胞系</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MCF-10A、人乳腺癌细胞系MDA-MB-231、小鼠乳腺癌细胞系4T1、人急性单核细胞白血病细胞系Thp1和小鼠巨噬细胞系Raw264.7。所有这些细胞系的身份已经通过</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >短串联重复序列</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分析验证。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >M</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CF-10A</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在</font>DMEM/F12培养基中</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >培养，补充</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >加入</font>5%马血清、1%青霉素和链霉素(Gibco，GrandIsland，NY，USA)、20ng/ml重组人表皮生长因子(EGF)、0.5&#956;g/ml氢化可的松、100ng/ml霍乱毒素和10&#956;g/ml胰岛素(aldrichsigma，中国</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >上海</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MDA-MB-231和4T1细胞在添加10%胎牛血清和1%青霉素和链霉素(Gibco)的DMEM培养基中培养。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Thp1和Raw264.7细胞在添加10%胎牛血清和1%青霉素和链霉素(Gibco)的RPMI-1640培养基中培养。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >所有细胞在含有</font>5%CO</span><sub><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:sub;" >2</span></sub><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的湿化培养箱中保持在</font>37</span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >100ng/ml phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich) </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >诱导</font>Thp1单核</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞附着和分化为巨噬细胞。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >以乳腺癌细胞系</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >MDA-M-231和4T1的细胞培养上清</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >液作</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >为条件培养</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >基</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >(CM)，诱导Thp1巨噬细胞和RAW264.7巨噬细胞向M2表型转化。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对于乳腺癌细胞与</font>TAMs的共培养，采用6孔或24孔跨</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >孔</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >共培养系统。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >简而言之，</font>transwell插入物被放置在含有乳腺癌细胞的6孔或24孔培养板中。TAMs置于上交换腔内。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Transwel</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >l</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >插入物由一个</font>0.4&#956;m的可渗透膜隔开，允许介质和可溶性分子的自由交换。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >消癖颗粒的制备及质量控制</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >从淫羊藿、</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >肉苁蓉</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >益母草</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、丹参、</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >郁金、</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >莪术、女贞子、制何首乌、牡蛎、鳖甲</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >10种中药的混合物中提取了</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。采用回流</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >萃取</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >法分别提取</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >采用高效液相色谱指纹图谱法</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对其进行质量控制。详细的制备和质量控制信息以前已经报道过</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >Liu</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2010;W</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >ang</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >and </font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >H</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >uang</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2010;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >Wang</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人，</font>2017)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >23-24,11</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >流式细胞仪分析</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >流式细胞仪</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >分析巨噬细胞表面标志物，鉴定巨噬细胞的表型。在浓度为</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >5×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;vertical-align:super;" >6</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞</font>/ml</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >浓度下，用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" >100&#956;l PBS溶液，对巨噬细胞进行简单的收集、洗涤和</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >悬浮</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >以</font>Thp1巨噬细胞为实验对象，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在</font>37</span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >条件下分别用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >F</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >ITC结合的F4/80抗体(SC-71085，Santa Cruz Biotechnology，美国加利福尼亚州圣克鲁斯)和PE结合的CD163抗体(12-1639-42，eBioscience </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >San</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Diego，美国加利福尼亚州)孵育30分钟。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对</font>Raw264.7巨噬细胞</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，在</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >37</span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >下用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >F</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >ITC结合的F4/80抗体(SC-71085，Santa Cruz)和PE结合的CD206抗体(141705，Biolegend，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >San</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;Diego,CA)孵育30分钟。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用</font>CD45-PE-Cy7(25-0451-82，eBioscience)、FITC-F4/80抗体(SC-71085，Santa Cruz)和PE-CD206抗体(141705，Biolegend)在37</span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >培</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >育</font>30</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分钟，用于对</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >小鼠</font>4T1-Luc异种移植物</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >原代巨噬细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >进行</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(0,0,0);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><font face="宋体" >表型分析</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >培养后，用</font>PBS洗涤细胞一次，然后用FC500流式细胞仪(富勒顿Beckman Coulter)或FACSAria </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >&#8546;</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >流式细胞仪</font>(BD Biosciences</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font><font face="宋体" >San</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;Diego,CA)进行分析。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >将</font>F4/80</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >/CD163</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >F4/80</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >/CD206</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群或</font>CD45</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >/F4/80</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >/CD206</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群定量为</font>M2型巨噬细胞。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >MTT</font><font face="宋体" >分析</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MTT法检测</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对乳腺上皮细胞、乳腺癌细胞和巨噬细胞的细胞毒性。总之，将细胞种植到密度为</font>5×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >3</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >/</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >孔</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的</font>96孔板中。细胞粘附后，分别用XPS浓度梯度法处理细胞24h和48h，以探讨XPS在TAMs存在下是否仍对乳腺癌细胞增殖有抑制作用，并与乳腺癌细胞和TAMs在24孔共培养体系中共培养。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >T</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >AM</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s以每孔3</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >×10</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >4</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞的密度接种在上部</font><font face="宋体" >transwell小室中，乳腺癌细胞以每孔5</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >×10</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >3</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞的密度接种在下部小室中，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞粘附后用</font>XPS进行连续浓度梯度处理48h，按照制造商的说明书，用MTT法检测细胞活力。MTT</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >测定以独立的三次重复进行。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >集落形成试验</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为了研究</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS对乳腺癌细胞集落形成的影响，将MDA-MB-231和4T1细胞分别接种于密度为</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >每孔</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2,000个细胞的6孔板中。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为了探讨在</font>TAMs存在</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >下</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS是否仍具有抑制</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >集落形成的作用，将乳腺癌细胞与</font>TAMs在24孔transwell共培养体系中共同培养。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >T</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >AM</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s以</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >3s×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >4</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个细胞</font><font face="宋体" >/孔的密度接种在上部transwell小室中，而乳腺癌细胞以</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >200</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个细胞</font><font face="宋体" >/孔的密度接种在下部小室中</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞贴壁后，用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >连续</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >浓度梯度</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS处理</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >48h，然后用新鲜培养基代</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >替。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >然后，细胞培养</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2周，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >所得菌落</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用</font>4%的多聚甲醛固定，再用考马斯蓝染色</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >乳腺肿瘤干细胞群体分析</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >根据制造商的说明，使用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >ALDEFLUOR干细胞鉴定试剂盒(01700，STEMCELL Technologies，加拿大温哥华)，用</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >流式细胞仪分析乳腺癌干细胞的数量。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >简单地说，将乳腺癌细胞种植在密度为</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >4×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >5</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个细胞</font><font face="宋体" >/孔的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >6孔板中。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为了进行乳腺癌细胞与</font>TAMs的共培养，将4s×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >5</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >TAMs种植在上</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >部</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的</font>transwell</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >室</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中，并将其插入到接种有</font>4×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >5</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个乳腺癌细胞</font>/</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >孔</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的</font>6孔培养板中。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >指定浓度的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS、CXCL1(人CXCL1，C597，Novoprotein，小鼠CXCL1,250-11-20，Peprotech，Rocky Hill，NJ，美国)或XPS和CXCL1联合处理48h。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >处理后收集</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌细胞，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >再悬浮在</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >500&#956;l ALDEFLUOR</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >TM</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >测定缓冲液中，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >然后，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >将细胞与</font><font face="宋体" >A</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >LDEFLUOR</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >TM</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >缓冲液</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在</font>37</span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >下孵育</font>30min</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >以</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >标记</font>ALDH</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >培养后，用</font>PBS洗涤细胞一次，用FC500流式细胞仪(Beckman)进行分析。定义ALDH</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群为乳腺</font>CSCs。用特异性抑制ALDH活性的</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >抑制剂</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >二乙氨基苯甲醛</font>(DEAB)控制ALDH染色中的背景荧光。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为了分析小鼠</font>4T1-Luc异种移植物中乳腺</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >SC</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的种群，首先采用机械法从小鼠乳腺肿瘤中分离原</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >发性</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌细胞，然后</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如上所示</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >进行乳腺</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >SC</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >种群分析。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >乳腺微球形成分析</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >将</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >以</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >1×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >5</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞</font>/</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >孔</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的超低密度接种</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >6孔</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >超低附着</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >板</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >上</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为了进行乳腺癌细胞与</font>TAMs的共培养，将4×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >5</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个</font>TAMs种植在上层的transwel</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >l</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >腔中，并将</font>transwell插入接种有1×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >5</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个乳腺癌细胞</font>/</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >孔</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的</font>6孔培养板中。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >然后</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >按提示</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS、CXCL1或XPS和CXCL1联合处理上述细胞48h。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用于乳腺微球</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >形成</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >测定</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的完整培养基为</font>DMEM/F12培养基，添加</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >有</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >1%青霉素-链霉素(Gibco)、2% B27补充剂(Gibco)、20ng/ml EGF、5&#956;g/ml胰岛</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >素和</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >0.4%牛血清白蛋白(BSA、Sigma-Aldrich)。在显微镜下</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >腺</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >微球的数量进行</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >定</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >量。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >实时荧光定量核酸扩增检测系统</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Trizol提取总RNA，并用primeScript</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >t</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >m</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >RT试剂盒</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >按照制造商的说明</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >逆转录成互补</font>cDNA。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用</font>SYBR pre</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >mix</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;E</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >x</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;TaqKit试剂盒(Takara)和Quant Studio6和7Flex Real-Time PCR系统(应用生物系统，福斯特市，加州，美国)进行RT-PCR。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >人</font><font face="宋体" >β-肌动蛋白(β-actin)的引物序列分别为5&#8242;-CCAACCGCGAGAAGATGA</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >-3&#8242;(正向)和5</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >＇</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >-CCAGAGGCGTACAGGGATAG-3&#8242;(反向)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >人</font><font face="宋体" >β-连环蛋白</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >β-catenin</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >）</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的引物序列为</font> 5</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >＇</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >-GCTTTCAGTTGAGCTGACCA</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >-3&#8242;(正向)和5&#8242;-CAAGTCCAAGATCAGCAGTCTC-3&#8242;(反向)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >人</font>OCT4基因的引物序列分别为5&#8242;-CAATTTGCCAAGCTCCTGA-3&#8242;(正向)和5&#8242;-AGATGGTCGTTTGGCTGAAT-3&#8242;(反向)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >人</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Nanog</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >基因的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >引物序列分别为</font>5&#8242;-ATGCCTCACACGGAGACTGT-3&#8242;(正向)和5&#8242;-CAGGGCTGTCCTGAATAAGC-3&#8242;(反向)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >人</font>CXCL1基因的引物序列分别为5&#8242;-AGGGAATTCACCCCAAGAAC-3&#8242;(</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >正向</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)和5&#8242;-ACTATGGGGGATGCAGGATT-3&#8242;(</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >反</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >向</font>)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >小鼠</font><font face="宋体" >β-肌动蛋白的引物序列分别为5</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >＇</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >-GGAGGGGGTTGAGGTGTT-3-3&#8242;(正向)和5&#8242;-GTGTGCACTTTTATTGGTCTCAA-3&#8242;(反向)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >小鼠</font><font face="宋体" >β-连环蛋白的引物序列分别为5&#8242;-ACAGCACCTTCAGCACTCT-3&#8242;(正向)和5&#8242;-AAGTTCTTGGCTATTACGACA-3&#8242;(反向)。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >小鼠</font>OCT4基因的引物序列为5&#8242;-CTGTAGGGAGGGCTTCGGGCACTT-3&#8242;(</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >正向</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)和5&#8242;-CTGAGGGCCAGGCAGGAGCACGAG-3&#8242;(反向)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >小鼠</font>Nanog基因的引物序列分别为5&#8242;-AGGGTCTGCTACTGAGATGCTCTG-3&#8242;(正向)和5&#8242;-CAACCACTGGTTTTTCTGCCACCG-3&#8242;(反向)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;mso-pagination:widow-orphan;
text-align:left;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >小鼠</font>CXCL1基因的引物序列分别为5&#8242;-GACTCCAGCCACACTCCAAC-3&#8242;(正向)和5&#8242;-TGACAGCGCAGCTCATTG-3&#8242;(反向)。</span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >蛋白质印迹法</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞按指示处理后，用</font><font face="宋体" >R</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >IPA</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（</font><font face="宋体" >Beyotime</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;Biotechnology</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，中国上海）进行裂解。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >根据制造商的说明书，用</font><font face="宋体" >Bicinch</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >oninic Acid</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >试剂盒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Sigma-Aldrich)对蛋白质浓度进行定量。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >将</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等量的蛋白质</font>(30&#956;g)在SDS-PAGE凝胶上</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >溶</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >解，转移到聚偏二氟乙烯微孔膜</font>(Millipore Billerica，MA，USA)上，并用β-actin(4970S，Cell signal Technology，CST，Boston，MA，USA)，CXCL1(AF5403，Affinity Biosciences，OH，USA)和β-catenin(51067-2-AP，美国芝加哥</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >Proteintech</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)的初级抗体进行检测。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >应用</font>Gel-Pro 4.0分析软件</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（</font><font face="宋体" >Media</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;Cybernetics,Maryland,USA</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >）</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >比较</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >条带</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的光密度</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >计算蛋白质在各组间</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >蛋白质</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的相对表达水平。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >酶联免疫吸附试验</font><font face="Arial Narrow" >(</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" >Elisa Assay</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >)</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >采用酶联免疫吸附试验</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Elisa)检测XPS对</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >T</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >AM</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s分泌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CXCL1的影响。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >简单地说，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >采用</font>6孔平板培养TAMs，并用</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >连续</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >浓度梯度</font>XPS处理48h。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >经</font>XPS处理后，将TAMs取出，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >再次以</font><font face="宋体" >5</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >×10</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >5</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个细胞</font><font face="宋体" >/孔的密度</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >接种到</font>6孔平板中，培养24h，收集各孔的细胞培养上清</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >液</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，按照生产说明书使用人</font>CXCL1酶联免疫吸附试剂盒(中国武汉USCN商业公司SEA041Hu)或小鼠CXCL1试剂盒(SEA041Mu,USCN Business)检测细胞培养上清液中CXCL1的浓度</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >双荧光素酶报告基因检测</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >采用双荧光素酶报告基因法研究</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS对CXCL1启动子活性的影响。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >根据生产说明</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >书</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，利用</font>Vigenefection (FH880806，Vigene &nbsp;Biosciences，济南)将CXCL1启动子质粒(Genecopeia，广州)转染</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >到</font><font face="宋体" >R</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >aw264.7衍生的TAMs。然后将转染细胞种植在密度为2×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >4</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个细胞</font><font face="宋体" >/孔</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的</font>96孔板中，并用</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >连续</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >浓度梯度</font>XPS处理48h。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;mso-pagination:widow-orphan;
line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >经</font>XPS处理后，收集各</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >孔</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的细胞培养上清液。根据生产厂家的说明，采用</font>Secrete-Pair</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >TM</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;D</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >ual</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;L</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >uminescence</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;Assay试剂盒(LF031，Genecopeia)，通过分析细胞培养上清液中</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >Gaussia</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >荧光素酶活性和分泌性碱性磷酸酶活性</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >来</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >检测</font>CXCL1启动子活性</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >组织免疫荧光</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对于免疫荧光分析，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺肿瘤冰冻切片用</font>4%多聚甲醛固定20分钟，用PBS洗涤3次，0.25% Triton X-100透化20分钟，然后室温</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >下</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用</font>5% BSA封闭1h，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对于</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >F4/80和CXCL1检测,</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >将</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >组织切片用</font>F4/80抗体(17-4801-80，eBioscience)和CXCL1抗体(AF5403，Affinity)在4</span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >通宵孵育，然后与</font>Alexa Fluor 555结合的抗大鼠IgG(4417S，CST)和Alexa Fluor 488结合的抗兔IgG(4412S，CST)孵</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >育</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2小时</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。对于</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >ALDH1A1检测</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >组织切片与</font>ALDH1A1抗体(BF0220，Affinity)在4</span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >孵育过夜，然后与</font>Alexa Fluor 555结合抗鼠IgG(A21422，Thermo Fisher)二级抗体孵育2h</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >4&#8242;</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >,</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >6-二氨基-2-苯基吲哚(DAPI，Sigma)</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用于</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >显示细胞核。采用</font>LSM710共聚焦显微镜(蔡司，耶拿，德国) </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >获得</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >荧光图像。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >动物实验</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >所有的活体实验都是根据我们机构的实验动物使用指南进行的，并且得到了广东省中医院动物护理和使用委员会</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(编号2018044)的批准。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在广东省中医院实验动物中心，在室温</font>20-25</span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >、相对湿度</font>45%-50%的无菌条件下饲养6周龄雌性Balb/c小鼠，并给予无菌食物和饮水。饲养设施维持在12小时的光照-黑暗周期。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >将</font>2×10</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >6</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >个</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >4T1-Luc细胞悬浮于200&#956;l PBS中，接种于小鼠乳腺脂肪垫皮下，建立4T1-Luc异种移植模型。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >当肿瘤直径达到平均</font>0.5cm时，将小鼠随机分为两组(每组6只)，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分别灌注生理盐水和</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS(1g/kg/d)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在整个治疗过程中，小鼠被称重，每</font>3天用卡尺测量它们的肿瘤。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >计算肿瘤体积</font>(v)的公式为:v=(长度)×(宽度)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >2</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >/2。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >腹腔注射</font>d-</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >荧光素</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(150mg/kg </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >weight</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>122799，PerkinElmer，Boston，USA)，每周使用IVIS Lumina XR</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >体内</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >成像系统</font>(Perkin Elmer)对小鼠进行成像，以监测肿瘤生长和转移。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >当肿瘤长到合适的大小时，对小鼠实施安乐死，并切除肿瘤。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用机械方法从新鲜乳腺肿瘤中分离出原代细胞，并进</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >行巨噬细胞表型分析或乳腺</font><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >SC</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s亚群分析。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >其余的肿瘤组织储存在零下</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >80</span><span style="mso-spacerun:'yes';font-family:宋体;line-height:150%;
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >℃</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如上所示</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >用于组织免疫荧光分析。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
mso-outline-level:2;line-height:150%;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >统计分析</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >数据采用平均值</font><font face="宋体" >&#177;标准差</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(SD)</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >表示</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。所有统计分析均使用</font>SPSS19.0软件(A</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >bbott</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >&nbsp;Laboratories美国芝加哥)进行。采用t检验和单</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >因素方差</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分析进行组间比较。</font>P&lt;0.05具有统计学意义</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >结果</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >共培养体系中</font><font face="Arial Narrow" >XPS</font><font face="宋体" >显著抑制乳腺癌细胞增殖和集落形成能力</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >首先，采用</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MTT法研究了XPS对乳腺上皮细胞和乳腺癌细胞的细胞毒性。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如图</font>1A所示，XPS处理24h或48h只能适度抑制人乳腺癌细胞MDA-MB-231和小鼠乳腺癌细胞4T1的增殖，而对MCF-10A细胞没有明显的细胞毒性。三种细胞的XPS的IC50值均在500&#956;g/ml以上。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >然</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >而</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在</font><font face="宋体" >2周培养期间</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >可</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >显著抑制乳腺癌细胞</font>MDA-MB-231和4T1的集落形成能力</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（图</font><font face="宋体" >1</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >B</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >）</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，表明</font>XPS对乳腺癌细胞增殖有长期抑制作用。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在肿瘤微环境中，癌细胞与多种细胞共存，其中以</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >T</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >AM</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >占最大比例。</font>TAMs通常表现</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >出免疫抑制</font><font face="宋体" >M</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2样表型，促进肿瘤生长并增强对治疗的抵抗力。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MDA-MB-231细胞条件培养基(CM)显著增加Thp1巨噬细胞的F4/80</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >/CD163</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >而</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >4T1-CM显著增加小鼠Raw264.7巨噬细胞的F4/80</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >/CD206</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群。这些结果表明，人</font>Thp1巨噬细胞和小鼠Raw264.7巨噬细胞均被成功地刺激为M2型巨噬细胞(图1C)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌细胞与这些</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >M</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2样表型的TAMs共同培养，利用transwel</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >l</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >共培养系统研究</font>TAMs存在时XPS能否抑制乳腺癌细胞的生长。如图1D所示，在共培养体系中，XPS处理48h可显著抑制乳腺癌细胞系MDA-MB-231和4T1的增殖。与TAMs共培养</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >时，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MDA-MB-231细胞</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >4T1</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >IC50值分别为402.05&#956;g/ml和92.64&#956;g/ml。同时，XPS还能</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >强烈抑制共培养体系中乳腺癌细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MDA-MB-231和4T1的集落形成能力(图1E)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >总之，</font>XPS能显著抑制乳腺癌细胞的增殖和集落形成能力，特别是与TAMs共培养时。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  align=center  style="text-align:center;" ><img width="528"  height="699"  src="2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞08089697.png" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;background:rgb(255,255,0);
mso-highlight:rgb(255,255,0);" ><o:p>&nbsp;</o:p></span></p><p class=MsoNormal  align=center  style="margin-bottom:6.0000pt;text-indent:21.0000pt;mso-char-indent-count:2.0000;
text-align:center;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >图</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >1|</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font>XPS）显</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >抑制共培养系统中乳腺癌细胞的增殖和集落形成能力。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:162.9500pt;mso-para-margin-left:15.5200gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >A）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >通过</font>MTT方法研究XPS在非恶性乳腺上皮细胞系MCF-10A和乳腺癌细胞系MDA-MB-231和4T1中的细胞毒性。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:162.9500pt;mso-para-margin-left:15.5200gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >B）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS(100~500&#956;g/ml)可显</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >抑制乳腺癌细胞系</font>MDA-MB-231和4T1的集落形成能力。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:162.9500pt;mso-para-margin-left:15.5200gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >C）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >人和小鼠巨噬细胞用乳腺癌细胞条件培养基</font>(CM)处理48小时后，均成功诱导为M2表型TAM。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:162.9500pt;mso-para-margin-left:15.5200gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >D）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS处理48小时可</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >显著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >抑制共培养系统中乳腺癌细胞系</font>MDA-MB-231和4T1的增殖。IC50值通过Bliss方法计算。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:162.9500pt;mso-para-margin-left:15.5200gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >E）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS可以</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >显著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >抑制共培养系统中乳腺癌细胞系</font>MDA-MB-231和4T1的集落形成能力。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:162.9500pt;mso-para-margin-left:15.5200gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >所有值均表示为平均值</font><font face="等线" >&#177;SD，n=3，**P&lt;0.05。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >XPS</font><font face="宋体" >抑制乳腺癌细胞和</font><font face="Arial Narrow" >TAMs</font><font face="宋体" >共培养系统中乳腺</font><font face="Arial Narrow" >CSCs</font><font face="宋体" >的自我更新活性</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CSCs被认为是乳腺癌细胞增殖和生长的启动细胞。因此，我们进一步研究了XPS对乳腺CSCs的影响。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >过度活跃的</font>aldehyde </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >dehydrogenase</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(ALDH)活性与</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >SC</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的生理特性密切相关</font>(Wang and Lei，2017)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >2</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >5</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，与</font>ALDH</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >-</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群相比，</font>ALDH</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群显示出更强的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >活</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >性</font>(Shao</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font><font face="宋体" >.</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >26</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如图</font>2A所示，XPS能显著降低MDA-MB-231细胞和4T1细胞中ALDH</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群的比例。乳腺</font>CSCs在非粘连的球形细胞集群中富集，被称为乳</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >腺微</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >球</font>(Wang等人，2014)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >27</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。因此，我们进一步研究</font>XPS能否抑制乳腺CSCs在乳腺癌细胞和TAMs共培养体系中的乳</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >腺</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >微球形成效率。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如图</font>2B所示，XPS治疗显著降低乳腺癌细胞和TAMs共同培养系统中乳</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >腺微</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >球数量。已有研究表明，多种干细胞转录因子在</font>CSCs中过度表达，如八聚体结合转录因子4(OCT4)、Nanog和β-catenin，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >它们</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >维持多能性</font>(Hattermann</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >.2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >28</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。为进一步验证</font>XPS对乳腺癌细胞共培养体系中干细胞表达的抑制作用，采用QPCR方法研究XPS对乳腺癌细胞</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >共培养体系中干细胞相关基因表达水平的影响。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如图</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >2C所示，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >共培养乳腺癌细胞中</font>XPS</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >显著</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >减弱</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >干细胞</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >相关基因的表达水平，包括</font><font face="宋体" >β-catenin、OCT4和Nanog。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >众所周知，</font><font face="宋体" >β-连环蛋白信号通路与乳腺CSCs的干细胞活性增强和耐药性增强有</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >关。此外，已经广泛报道</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >β-连环蛋白可以直接上调OCT4(Kelly</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2011</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Lee</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2014</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Qi</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2016</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Yong</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >29-32</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font>Nanog(Takao.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2007</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Li.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2013</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Yong.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2016</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Yu.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2017)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >33-35</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >，</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >32</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在多种癌细胞和</font>CSCs中的转录基因和蛋白表达。因此，我们只能进一步研究XPS是否能降低β-连环蛋白的表达水平。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如图</font>2D所示，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >蛋白质印迹法</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分析进一步证实，</font>XPS也能显著降低共培养乳腺癌细胞中β-连环蛋白的表达水平。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >结果表明，</font>XPS可抑制乳腺癌细胞和TAMs共培养系统中乳腺CSCs的自我更新活性。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  align=center  style="text-align:center;" ><img width="507"  height="684"  src="2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞080810982.png" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=MsoNormal  align=center  style="margin-top:5.0000pt;margin-bottom:6.0000pt;text-indent:21.0000pt;
mso-char-indent-count:2.0000;text-align:center;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >图</font><font face="等线" >2 |消癖颗粒（XPS）抑制乳腺癌细胞和肿瘤相关巨噬细胞（TAMs）共培养系统中乳腺癌干细胞（CSCs）的自我更新活性。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:184.2500pt;mso-para-margin-left:17.5500gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >A）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS处理48小时可显</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >降低</font>MDA-MB-231细胞和4T1细胞与TAM共培养时ALDH</span><sup><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >亚群的比例。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:184.2500pt;mso-para-margin-left:17.5500gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >B）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS处理48小时显</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >降低了共培养乳腺癌细胞的乳腺</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >微</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >球数量。比例尺</font>= 100&#956;m。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:184.2500pt;mso-para-margin-left:17.5500gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >C）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS处理48小时强烈减弱了共培养的乳腺癌细胞中β-连环蛋白、OCT4和Nanog的mRNA表达水平。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:184.2500pt;mso-para-margin-left:17.5500gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >D）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS处理48小时可显</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >减弱共培养的乳腺癌细胞中</font><font face="等线" >β-连环蛋白的蛋白表达水平。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:184.2500pt;mso-para-margin-left:17.5500gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >所有值均表示为平均值</font><font face="等线" >&#177; SD，n=3</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >，</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >**P &lt; 0.05。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:8.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >XPS</font><font face="宋体" >抑制</font><font face="Arial Narrow" >M</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >表型极化、</font><font face="Arial Narrow" >C</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" >XCL1</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >表达和</font><font face="Arial Narrow" >T</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" >AM</span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >s</font><font face="宋体" >的分泌</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >大量研究表明，肿瘤微环境中的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >TAMs可以促进肿瘤的生长。因此，我们推测XPS可以通过调节TAMs来抑制乳腺癌的生长。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如图</font>3A所示，XPS能显著抑制raw264.7衍生的TAMs的增殖，而对Thp1衍生的TAMs没有明显的细胞毒性。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >这些结果表明，</font>XPS可能通过其他机制而不是通过直接的细胞毒作用来调节TAMs。TAMs通常表现出促肿瘤生长的M2表型，促进肿瘤生长并增强对治疗的抵抗力。然而，巨噬细胞具有高度的可塑性，并能转化为抗肿瘤M1</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >表型</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Parisi等人，2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >19</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如图</font>3B所示，XPS能显著抑制乳腺癌细胞</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >条件培养基</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >诱导</font>TAMs的 M2表型极化。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >接下来，重要的是研究</font>XPS诱导的TAMs极化变化如何在共培养系统中引起乳腺CSCs种群的强烈变化。由于乳腺癌细胞和TAMs在</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >transwell</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >共培养体系中被</font>0.4&#956;m的可渗透膜分离，只允许介质和可溶性分子的自由交换，而不允许细胞间的直接相互作用，因此我们推测TAMs分泌的一些促肿瘤分子可能被XPS抑制，从而削弱TAMs对乳腺CSCs自我更新的促进作用。CXCL1是TAMs分泌的最丰富的趋化因子(Palomino</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Marti</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2015</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Wang等，2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >36</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >-</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >37</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >酶联免疫吸附试验表明，</font>XPS能显著抑制TAMs分泌CXCL1，呈剂量依赖性(图3C)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >蛋白质印迹法</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >和</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >实时荧光定量（</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >QPCR</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >）</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >结果进一步证实</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >能显著抑制人和小鼠</font>TAMs中CXCL1蛋白表达水平(图3D，</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >E</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >)和mRNA转录(图3F)，且呈剂量依赖性。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >双荧光素酶报告基因实验表明</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS能抑制肿瘤细胞CXCL1基因的启动子活性。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >结果表明，</font>XPS可抑制M2表型极化和CXCL1的表达及TAMs的分泌。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  align=center  style="text-align:center;" ><img width="552"  height="617"  src="2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞080812029.png" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=MsoNormal  align=center  style="margin-top:5.0000pt;margin-bottom:6.0000pt;text-indent:21.0000pt;
mso-char-indent-count:2.0000;text-align:center;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >图</font> <font face="等线" >3 |消癖颗粒(XPS)抑制M2表型极化、C-X-C基序趋化因子配体1(CXCL1)的表达和肿瘤相关巨噬细胞(TAM)的分泌。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:85.0500pt;mso-para-margin-left:8.1000gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >A）MTT实验表明XPS(100~500 &#956;g/ml)可以强烈抑制Raw264.7来源的TAMs的增殖而对Thp1来源的TAMs没有表现出明显的细胞毒性。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:85.0500pt;mso-para-margin-left:8.1000gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >B）XPS处理48小时可以显著抑制由乳腺癌细胞条件培养基诱导的TAM的M2表型极化。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:85.0500pt;mso-para-margin-left:8.1000gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >C） Elisa测定表明XPS处理48小时可以以剂量依赖性方式显著抑制TAM分泌CXCL1。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:85.0500pt;mso-para-margin-left:8.1000gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >D-E）蛋白质印迹和QPCR结果进一步证实，消癖颗粒处理48小时可以显著抑制人和小鼠TAM中的CXCL1蛋白表达水平（D）和CXCL1 mRNA转录水平（E）。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:85.0500pt;mso-para-margin-left:8.1000gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >F）双荧光素酶报告基因检测表明XPS处理48小时可以抑制Raw264.7衍生的TAM中CXCL1基因的启动子活性。所有值均表示为平均值&#177; SD，n = 3，**P &lt; 0.05。</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;color:rgb(12,12,12);font-size:15.0000pt;
mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >XPS</font><font face="宋体" >通过调控</font><font face="Arial Narrow" >TAMs/CXCL1</font><font face="宋体" >通路抑制乳腺</font><font face="Arial Narrow" >CSCs</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;mso-pagination:widow-orphan;mso-outline-level:2;
line-height:150%;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >由于</font>XPS能显著抑制乳腺癌细胞系CXCL1的表达和分泌，因此进一步研究CXCL1是否是XPS抑制乳腺癌细胞系CXCL1的关键分子具有重要意义。如图4A、B所示，CXCL1能显著增加乳腺癌细胞中的ALDH</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群和乳</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >腺</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >微球数量。同时，</font>CXCL1能够抑制XPS对乳腺CSCs和乳腺微球形成能力的影响(图2A，B和图4A，B)。QPCR检测进一步表明CXCL1可提高乳腺癌细胞干细胞相关基因β-catenin、OCT4和Nanog的mRNA表达水平，同时消除XPS对上述基因mRNA表达水平的抑制作用(图4C)。蛋白质印迹法分析进一步证实CXCL1能提高乳腺癌细胞中β-catenin蛋白的表达水平，同时逆转XPS对共培养乳腺癌细胞中β-catenin蛋白表达的抑制作用(图4D)。结果表明，XPS可通过抑制TAMs/CXCL通路，抑制乳腺癌细胞和TAMs共培养系统中CSCs的自我更新活性。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;color:rgb(12,12,12);font-size:12.0000pt;
mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  align=center  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;text-align:center;" ><img width="404"  height="497"  src="2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞080812862.png" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=MsoNormal  align=center  style="margin-top:5.0000pt;margin-bottom:6.0000pt;text-indent:21.0000pt;
mso-char-indent-count:2.0000;text-align:center;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >图</font><font face="等线" >4 |消癖颗粒(XPS)通过调节肿瘤相关巨噬细胞(TAM)/C-X-C 基序趋化因子配体1 (CXCL1)通路抑制乳腺癌干细胞(CSC)。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:63.7500pt;mso-para-margin-left:6.0700gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >A</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >-B</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >CXCL1刺激48小时可以</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >抵消消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >对共培养乳腺癌细胞中乳腺</font>CSCs亚群和乳腺球形成能力的抑制作用。比例尺=100&#956;m。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:63.7500pt;mso-para-margin-left:6.0700gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >C）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >QPCR检测表明CXCL1刺激48小时可以</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >抵消消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >对共培养乳腺癌细胞中干细胞相关基因（包括</font><font face="等线" >β-catenin、OCT4和Nanog）的mRNA表达水平的抑</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >制作用。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-left:63.7500pt;mso-para-margin-left:6.0700gd;text-indent:21.0000pt;
mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >D）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >蛋白质印迹分析进一步证实</font>CXCL1处理48小时可以</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >抵消消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >对共培养的乳腺癌细胞中</font><font face="等线" >β-连环蛋白表达的抑制作用。所有值均表示为平均值&#177;SD，n = 3，**P &lt; 0.05。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="Arial Narrow" >XPS</font><font face="宋体" >在体内抑制乳腺肿瘤生长及乳腺</font><font face="Arial Narrow" >CSCs</font><font face="宋体" >活性</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >基于我们的体外研究结果，在体内验证</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS的抗乳腺癌活性和机制是非常重要的。将荧光素酶标记的4T1-Luc细胞植入Balb/c小鼠乳腺，建立乳腺癌异种移植瘤模型。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在小鼠</font>4T1-Luc异种移植模型中，XPS能有效地抑制乳腺肿瘤的生长(图5A，B)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >此外，与生理盐水组相比，没有观察到治疗相关的死亡率或体重明显下降</font>(图5C)，这意味着XPS给药没有引起额外的毒性和副作用。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >值得注意的是，体内成像实验也表明</font>XPS能抑制乳腺癌细胞系4T1-Luc的转移效应(图5A)，提示XPS也可能具有体</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >内抗转移活性。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >此外，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS能显著降低4T1-Luc异种移植物体内巨噬细胞</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的浸润程度和</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >M2表型极化。与此同时，与我们的体外研究结果一致，XPS在体内强烈减弱了乳腺肿瘤组织中CXCL1的表达(图5D，E)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >这些结果表明，</font>XPS在体内也可能抑制TAMs的M2表型转化和CXCL1分泌。此外，XPS能显著降低4T1-Luc异种移植物中ALDH</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >亚群的比例，抑制</font>ALDH1A1的表达，提示XPS也能抑制体内乳腺CSCs的活性(图5F，G)。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >如补充图</font>1和补充材料与方法所示，与生理盐水组相比，TAMs联合注射能显著增加乳腺肿瘤的生长和乳腺CSCs的数量。此</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >外，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS治疗和CXCL1基因敲除可部分消除TAMs对乳腺肿瘤生长和乳腺CSCs群的促进作用。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >更重要的是，</font>CXCL1在乳腺癌细胞系中的过表达部分逆转了XPS对乳腺肿瘤生长和乳腺CSCs群体的抑制作用。结果表明，XPS可通过调节TAMs/CXCL1通路抑制乳腺肿瘤的生长和乳腺CSCs的活性。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  align=center  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;text-align:center;" ><img width="552"  height="682"  src="2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞0808.files/2、消癖颗粒通过抑制肿瘤TAMsCXCL1通路抑制乳腺癌干细胞080813869.png" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p>&nbsp;</o:p></span></p><p class=MsoNormal  align=center  style="margin-top:5.0000pt;margin-bottom:6.0000pt;text-indent:21.0000pt;
mso-char-indent-count:2.0000;text-align:center;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >图</font> <font face="等线" >5 |消癖颗粒(XPS)在体内抑制乳腺肿瘤生长和乳腺癌干细胞(CSC)活性。</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:21.0000pt;mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >A）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >小鼠</font>4T1-Luc异种移植模型体内成像实验的代表性图片。通过将荧光素酶标记的4T1-Luc细胞植入Balb/c小鼠的乳腺，建立了乳腺癌异种移植物。携带4T1-Luc异种移植物的小鼠通过胃内灌注接受盐水或XPS（1 g/kg/天）。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:21.0000pt;mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >B）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS给药可有效抑制体内小鼠4T1-Luc异种移植模型中的乳腺肿瘤生长。n = 6. </span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:21.0000pt;mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >C）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >生理盐水组和</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >消癖颗粒</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >组之间的小</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >鼠体重没有显著差异，这意味着</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS没有额外的毒副作用。n = 6. </span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:21.0000pt;mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >D</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >-E</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS给药显</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >降低了巨噬细胞的浸润程度以及它们的</font>M2表型极化和C-X-C基序趋化因子配体1 (CXCL1) 在体内4T1-Luc异种移植物中的表达。n = 3.</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:21.0000pt;mso-char-indent-count:2.0000;" ><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >（</font><font face="等线" >F</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >-G</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >）</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" >XPS给药显</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >著</font></span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >降低了</font>ALDH</span><sup><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;vertical-align:super;" >+</span></sup><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><font face="等线" >亚群</font>(F)的比例并抑制了体内4T1-Luc异种移植物中ALDH1A1 (G) 的表达水平。n = 3。比例尺= 20 &#956;m。所有值均表示为平均值&#177; SD，** P &lt; 0.05。</span><span style="mso-spacerun:'yes';font-family:等线;mso-bidi-font-family:'Times New Roman';
font-size:10.5000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >讨论</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺癌的高发病率和死亡率严重威胁妇女健康</font> </span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Bray等人，2018年)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >2</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。几十年来，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >人们一直在努力寻找和开发新的乳腺癌靶点或治疗策略。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >虽然许多细胞毒性药物或细胞抑制药物已经被开发用于治疗乳腺癌，如蒽醌类、烷化剂、生物碱和抗代谢物，但由于肿瘤内部和肿瘤间的异质性，它们的治疗效果令人失望</font>(Jin and Ye</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2013</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Yuan.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >3</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >8</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >-</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >39</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >最近，传统的策略已经</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >偏向于</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >对肿瘤微环境的理解，从而使肿瘤细胞与其宿主之间的免疫动力学改变成为可能</font>(Kjeldsen等，2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >4</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >0</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。一个旨在破</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >解宿主免疫系统的新型药物时代正在稳步来临。新出现的免疫治疗策略，包括免疫检查点抑制剂、治疗性疫苗和过继性细胞治疗，在</font><font face="宋体" >“难以治疗”的癌症类型和以前难治的病例中带来了难以置信的临床疗效和延长生存期。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在本研究中，我们证明了现有的抗乳腺增生药物</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >XPS通过调节M2表型极化及其CXCL1</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分泌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >在</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >体外</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >显著抑制</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >乳腺</font>CSCs。更重要的是，XPS能抑制小鼠4T1-Luc异种移植物的体内生长。提示XPS可能通过免疫调节作用抑制乳腺癌的发生。这一发现为XPS在乳腺癌治疗中的应用提供了科学依据。此外，本研究还强调了肿瘤免疫微环境</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >是</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >中药抗肿瘤药理活性的关键机制。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CSCs被认为是癌症发生和发展的起源和驱动力(Nilendu.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2017)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >41</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >SC</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的微环境由免疫细胞等多种成分组成。免疫细胞与</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >SC</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >之间复杂的相互作用正受到越来越多的关注。例如，据报道，与非</font>CSCs相比</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CSCs表</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >现出较低的免疫原性，它们可能抑制多种肿瘤相关抗原，从而限制了适应性免疫系统识别它们的效力，并导致癌症复发或转移</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Di Tomaso.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2010</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Chikamatsu.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2011</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Volonte.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2014)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >42-44</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font>CSCs可以分泌多种分子，如TGF-β，可以促进Treg向iTreg分化，从而降低其抗肿瘤免疫力(Dunn等人，2004;Bruttel和Wischhusen</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2014</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Maccalli等人，2014)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >45-47</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。此外，</font>CSCs可以将免疫抑制的</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >免疫细胞募集到肿瘤的微环境中，因此有利于它们自己的生存</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Vahidian等人，2019)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >14</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。关于</font>TAMs，据报道，包括CSF-1和CCL2在内的多种因子在CSCs微环境中富集，并能募</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >集</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >极化</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >为</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >免疫抑制</font>M2表型的巨噬细胞</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Wu等人，2010</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Zhou等人，2015)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >48</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >-</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >49</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。此外，</font>TAMs还可以通过多种方式介导CSCs的功能(Jinushi.，2012</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Yang.，2013)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >50</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >-</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >51</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。例如，据报道，</font>TAMs</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >是</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >防止肿瘤微环境中的</font>CSCs持续免疫监测</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >所</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >必</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >需</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的</font>(Wynn等人，2013</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Noy和Pollard，2014</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Sarkar等人，2014)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >5</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >2</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >-</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >54</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。此外，</font>TAMs通过释放TGF-β和有利于</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >干细胞的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >细胞因子</font>IL-8和CXCL12</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Plaks等）</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >55</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，激活</font>CSCs的Hedgehog信号通路，促进CSCs的增殖和侵袭。本研究表明，抑制乳腺癌细胞分泌CXCL1是一种抑制乳腺癌细胞自我更新活性的新工具。这些结果表明，利用免疫调节方法靶向CSCs可能是消除这些肿瘤起始细胞的有效途径。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >肿瘤微环境中的免疫细胞，包括</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >TAMs，可以释放趋化因子作为炎症介质，通过激活更多的免疫抑制细胞到肿瘤基质中，最终促进肿瘤的发生和转移，从而影响癌症的发展</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >De la Fuente Lopez</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等）</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >56</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。趋化因子是细胞因子的一个大家族，一般分子量在</font>7-15kda之间，具有多效性功能(细胞趋化、细胞因子分泌、细胞增殖和存活)。有两个主要的趋化因子亚家族基于半胱氨酸残基的位置:CXC和CC。目前，大约有50种内源性趋化因子配体被描述，而CXCL1是由TAMs分泌的最丰富的趋化因子(Palomino和Marti</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2015</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >Wang等人，2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >5</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >7</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >，</font><font face="宋体" >3</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >7</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。越</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >来越多的研究表明</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CXCL1在多种肿瘤的检测和预后预测中是一个很有前</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >景</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的指标。例如，与</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >临近的非癌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >组织相比，</font>CXCL1在胃癌组织中的表达上调。CXCL1上调是影响胃癌患者生存的独立预后因素之一，与胃癌患者的肿瘤进展显著相关(Cheng等，2011)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >58</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。在膀胱癌中，浸润性膀胱癌患者尿液中</font>CXCL1水平显著高于非浸润性膀胱癌患者和正常对照组，这表明CXCL1是预测膀胱癌浸润的独立因素(Kawanishi等，2008)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >5</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >9</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。更重要的是，膀胱癌组织中高浓度的</font>CXCL1水平与膀胱癌中增加的TAMs浸润和病理分期呈正相</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >关</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >(Kawanishi等人，2008</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >M</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >iyake</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人，</font>2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >5</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >9</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >-</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >60</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。关于乳腺癌，</font>Zou等人报告说，乳腺癌间质中CXCL1表达增加与患者预后不良有关(Zou等人，2014)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >61</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。我们以前也报道过来自</font>TAMs的CXCL1在体外可以促进乳腺癌细胞的上皮间质转化、迁移和侵袭。此外，CXCL1基因沉默可抑制TAMs诱导的乳腺癌异种移植物的生长和肺转移。(Wang.</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >，</font>2018)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >3</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >7</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >机制研究进一步证实</font>NF-&#954;B/SOX4信号通路是TAMs/CXCL1促进乳腺癌转移的主要作用靶点。这与现有的报道</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >一致，即</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CXCL1介导的TAMs和癌细胞之间的相互作用可以促进人类膀胱癌的肿瘤进展(Miyake等，2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >6</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >0</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。此外，</font>TAM</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分泌的</font>CXCL1可以</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >募集</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >MDSCs进入肿瘤微环境，其分泌的趋化因子包括S100A8/9，增强癌细胞存活、化疗耐药性、转移和转移</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >微环境</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >形成</font>(Acharyya等人，2012</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >；</font><font face="宋体" >Miyake</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >等人，</font>2016)</span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >6</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >2</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >，</font><font face="宋体" >6</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >0</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。在本研究中，我们发现</font>TAM</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >分泌</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >的</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >CXCL1可以促进乳腺癌细胞的自我更新活性。这与现有的报道一致，即炎症趋化因子CXCL1可以通过增强CD133的表达和aldehyde活性来增强结肠CSC的特性</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >（</font><font face="宋体" >Hsu等2</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >018</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >）</font></span><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >【</font><font face="宋体" >6</font></span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" >3</span></sup><sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;
vertical-align:super;" ><font face="宋体" >】</font></span></sup><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >。考虑到乳腺</font>CSCs是乳腺癌发生的起源细胞，也是乳腺癌发展的驱动力，肿瘤微环境中的TAMs/CXCL1通路可能在调节乳腺癌发展和预后方面发挥重要作用，有望成为未来乳腺癌诊断和预后的生物标志物。</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >总结</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="text-indent:24.0000pt;mso-char-indent-count:2.0000;line-height:150%;" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >结论</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >:XPS可能通过阻断CXCL1介导的TAMs与CSCs之间的相互作用而抑制乳腺癌的生长。本研究不仅揭示了XPS在乳腺癌治疗中的免疫调节机制，而且为TAMs/CXCL1作为乳腺</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >C</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" >SC</span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >s</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >消除的潜在分子靶点提供了新的见解。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><b><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >数据可用性声明</font></span></b><b><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-weight:bold;font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></b></p><p class=MsoNormal  style="margin-top:14.0000pt;margin-bottom:7.0000pt;text-indent:24.0000pt;
mso-char-indent-count:2.0000;mso-pagination:widow-orphan;mso-outline-level:2;
line-height:150%;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><font face="宋体" >本项研究生成的所有数据集都包含在文章</font><font face="宋体" >/补充材料中。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-bidi-font-family:'Times New Roman';
line-height:150%;font-size:12.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-top:7.0000pt;margin-bottom:7.0000pt;mso-pagination:widow-orphan;
text-align:left;mso-outline-level:2;line-height:150%;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:'Arial Narrow';
mso-hansi-font-family:'Arial Narrow';line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><font face="宋体" >参考文献</font></span><span style="mso-spacerun:'yes';font-family:'Arial Narrow';mso-fareast-font-family:宋体;
mso-bidi-font-family:宋体;line-height:150%;color:rgb(12,12,12);
font-size:15.0000pt;mso-font-kerning:0.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., and Wang, X. S. (2015). Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385 (9972), 977–1010. doi: 10.1016/S0140-6736(14)62038-9</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68 (6), 394–424. doi: 10.3322/caac.21492</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Ali, I., Wani, W. A., and Saleem, K. J. C. T. (2011). Cancer scenario in India with future perspectives. Cancer Ther. 8 (8), 56–70.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Chia, S., Swain, S. M., Byrd, D. R., and Mankoff, D. A. (2008). Locally advanced and inflammatory breast cancer. J. Clin. Oncol. 26 (5), 786–790. doi: 10.1200/JCO.2008.15.0243</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Nie, J., Zhao, C., Deng, L. I., Chen, J., Yu, B., and Wu, X. (2016). Efficacy of traditional Chinese medicine in treating cancer. Biomed. Rep. 4 (1), 3–14. doi: 10.3892/br.2015.537</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >6】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Liao, Y. H., Li, C. I., Lin, C. C., Lin, J. G., Chiang, J. H., and Li, T. C. (2017). Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J. Cancer Res. Clin. Oncol. 143 (12), 2425–2435. doi: 10.1007/s00432-017-2491-6</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >7】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Tian, H., Qin, W., Wu, W., Guo, P., Lu, Y., and Liu, P. (2015). Effects of traditional chinese medicine on chemotherapy-induced myelosuppression and febrile neutropenia in breast cancer patients. Evid. Based Complement Alternat. Med.2015, 736197. doi: 10.1155/2015/736197</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >8】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Wang, W., Xu, L., and Shen, C. (2015). Effects of traditional chinese medicine in treatment of breast cancer patients after mastectomy: a meta-analysis. Cell Biochem. Biophys. 71 (3), 1299–1306. doi: 10.1007/s12013-014-0348-z</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >9】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Lin, Y. H., and Chiu, J. H. (2011). Use of Chinese medicine by women with breast cancer: a nationwide cross-sectional study in Taiwan. Complement Ther. Med.19 (3), 137–143. doi: 10.1016/j.ctim.2011.04.001</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Santisteban, M., Reynolds, C., Barr Fritcher, E. G., Frost, M. H., Vierkant, R. A., and Anderson, S. S. (2010). Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res. Treat. 121 (2), 431–437. doi: 10.1007/s10549-009-0534-7</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Wang, N., Zheng, Y., Gu, J., Cai, Y., Wang, S., and Zhang, F. (2017). Network</span><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:9.0000pt;
mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >-</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >pharmacology-based validation of TAMS/CXCL-1 as key mediator of XIAOPI formula preventing breast cancer development and metastasis. Sci. Rep. 7 (1), 14513. doi: 10.1038/s41598-017-15030-3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Cohen, I., Tagliaferri, M., and Tripathy, D. (2002). Traditional Chinese medicine in the treatment of breast cancer. Semin. Oncol. 29 (6), 563–574. doi: 10.1053/sonc.2002.50005</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Xie, W. J., Lin, Y., Liang, Q. R., Zhong, S. W., Situ, H. L., and Chen, Y. (2018). [Analysis of professor Lin Yi’s experience for metastasis breast cancer by data mining]. Zhongguo Zhong Yao Za Zhi 43 (15), 3198–3204. doi: 10.19540/j.cnki.cjcmm.2018.0095</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >4</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., and Baradaran, B. (2019). Interactions between cancer stem cells, immune system and some environmental components: Friends or foes?. Immunol. Lett.208, 19–29. doi: 10.1016/j.imlet.2019.03.004</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >5</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Shima, H., Yamada, A., Ishikawa, T., and Endo, I. (2017). Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?. Gland. Surg.6 (1), 82–88. doi: 10.21037/gs.2016.08.03</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >6</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., and Merad, M. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24 (5), 541–550. doi: 10.1038/s41591-018-0014-x</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >7</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Lao, L., Fan, S., and Song, E. (2017). Tumor associated macrophages as therapeutic targets for breast cancer. Adv. Exp. Med. Biol. 1026, 331–370. doi: 10.1007/978-981-10-6020-5_16</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-line-height-alt:12pt;
background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >8</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >De la Fuente Lopez, M., Landskron, G., Parada, D., Dubois-Camacho, K., Simian, D., and Martinez, M. (2018). The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumorassociated macrophage markers in colorectal cancer. Tumour Biol. 40 (11), 1010428318810059. doi: 10.1177/1010428318810059</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >1</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >9</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Parisi, L., Gini, E., Baci, D., Tremolati, M., Fanuli, M., and Bassani, B. (2018). Macrophage polarization in chronic inflammatory diseases: killers or builders?. J. Immunol. Res. 2018, 8917804. doi: 10.1155/2018/8917804</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Mills, C. D., Lenz, L. L., and Harris, R. A. (2016). A breakthrough: macrophage-directed cancer immunotherapy. Cancer Res. 76 (3), 513–516. doi:&nbsp;10.1158/0008-5472.CAN-15-1737</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;text-align:left;
mso-outline-level:2;mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Hollmen, M., Karaman, S., Schwager, S., Lisibach, A., Christiansen, A. J., and Maksimow, M. (2016). G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunol. 5 (3), e1115177. doi: 10.1080/2162402X.2015.1115177</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Tang, X. (2013). Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 332 (1), 3–10. doi: 10.1016/j.canlet.2013.01.024</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Liu, H. (2010). Study on determination of Xiaopi Granules by HPLC. China Medical Herald 7 (27), 47–48. doi: 10.3969/j.issn.1673-7210.2010.27.024</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >4</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Wang, D., and Huang, N. (2010). Determination of tanshinone in Xiaopi Granules by TLC. Guangzhou Medical J. 41 (05), 59–60. doi: 10.3969/j.issn.1000-8535.2010.05.029</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >5</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Wang, Y. P., and Lei, Q. Y. (2017). Perspectives of reprogramming breast cancer metabolism. Adv. Exp. Med. Biol. 1026, 217–232. doi: 10.1007/978-981-10-6020-5_10</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >6</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Shao, J., Fan, W., Ma, B., and Wu, Y. (2016). Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics. Mol. Med. Rep. 14 (6), 4991–4998. doi: 10.3892/mmr.2016.5899</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >7</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Wang, Z., Wang, N., Li, W., Liu, P., Chen, Q., and Situ, H. (2014). Caveolin-1 mediates chemoresistance in breast cancer stem cells via beta-catenin/ABCG2 signaling pathway. Carcinogenesis 35 (10), 2346–2356. doi: 10.1093/carcin/bgu155</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >8</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Hattermann, K., Fluh, C., Engel, D., Mehdorn, H. M., Synowitz, M., and Mentlein,&nbsp;R. (2016). Stem cell markers in glioma progression and recurrence. Int. J. Oncol. 49 (5), 1899–1910. doi: 10.3892/ijo.2016.3682</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >2</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >9</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Kelly, K. F., Ng, D. Y., Jayakumaran, G., Wood, G. A., Koide, H., and Doble, B. W. (2011). beta-catenin enhances Oct-4 activity and reinforces pluripotency through a TCF-independent mechanism. Cell Stem. Cell 8 (2), 214–227. doi: 10.1016/j.stem.2010.12.010</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Lee, S. H., Koo, B. S., Kim, J. M., Huang, S., Rho, Y. S., and Bae, W. J. (2014). Wnt/beta-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating Oct4. J. Pathol.234 (1), 99–107. doi: 10.1002/path.4383</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Qi, Y. F., Wu, L., Li, Z. Q., Wu, M. L., Wang, H. F., and Chan, K. Y. (2016). Nodal signaling modulates the expression of Oct-4 via nuclear translocation of betacatenin in lung and prostate cancer cells. Arch. Biochem. Biophys. 608, 34</span><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:9.0000pt;
mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >–</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >41. doi: 10.1016/j.abb.2016.07.003</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Yong, X., Tang, B., Xiao, Y. F., Xie, R., Qin, Y., and Luo, G. (2016). Helicobacter pylori upregulates Nanog and Oct4 via Wnt/beta-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer. Cancer Lett.374 (2), 292–303. doi: 10.1016/j.canlet.2016.02.032</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Takao, Y., Yokota, T., and Koide, H. (2007). Beta-catenin up-regulates Nanog expression through interaction with Oct-3/4 in embryonic stem cells. Biochem. Biophys. Res. Commun. 353 (3), 699–705. doi: 10.1016/j.bbrc.2006.12.072</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;text-align:left;
mso-outline-level:2;mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >4</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Li, X. Q., Yang, X. L., Zhang, G., Wu, S. P., Deng, X. B., and Xiao, S. J. (2013). Nuclear beta-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. J. Transl. Med. 11, 114. doi: 10.1186/1479-5876-11-114</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >5</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Yu, S. J., Kim, H. J., Lee, E. S., Park, C. G., Cho, S. J., and Jeon, S. H. (2017). betaCatenin accumulation is associated with increased expression of nanog protein and predicts maintenance of MSC self-renewal. Cell Transplant 26 (2), 365–377. doi: 10.3727/096368916X693040</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >6</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Palomino, D. C., and Marti, L. C. (2015). Chemokines and immunity. Einstein (Sao Paulo) 13 (3), 469–473. doi: 10.1590/S1679-45082015RB3438</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >7</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Wang, N., Liu, W., Zheng, Y., Wang, S., Yang, B., and Li, M. (2018). CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB/SOX4 signaling. Cell Death Dis. 9 (9), 880. doi: 10.1038/s41419-018-0876-3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >3</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >8</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Jin, S., and Ye, K. J. (2013). Targeted drug delivery for breast cancer treatment. Recent Patents Anti-Cancer Drug Discovery 8 (2), 143–153. doi: 10.2174/1574892811308020003</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >39</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Yuan, T., Yue, W., Kiani, M. F., and Wang, B.J.C.B.C. (2016). Classification, treatment strategy, and associated drug resistance in breast cancer. Clin. Breast Cancer 16 (5), 335–343. doi: 10.1016/j.clbc.2016.05.012</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Kjeldsen, J. W., Donia, M., and Svane, I. M. (2018). Cancer immunotherapy. Ugeskr. Laeger. 180 (21).</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Nilendu, P., Kumar, A., Kumar, A., Pal, J. K., and Sharma, N. K. (2017). Breast cancer stem cells as last soldiers eluding therapeutic burn: a hard nut to crack. Int. J. Cancer. 142 (1), 7–17. doi: 10.1002/ijc.30898</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Di Tomaso, T., Mazzoleni, S., Wang, E., Sovena, G., Clavenna, D., and Franzin, A. (2010). Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16 (3), 800–813. doi: 10.1158/1078-0432.CCR-09-2730</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Chikamatsu, K., Takahashi, G., Sakakura, K., Ferrone, S., and Masuyama, K. (2011). Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck 33 (2), 208–215. doi: 10.1002/hed.21420</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >4</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Volonte, A., Di Tomaso, T., Spinelli, M., Todaro, M., Sanvito, F., and Albarello, L. (2014). Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J. Immunol. 192 (1), 523–532. doi: 10.4049/jimmunol.1301342</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >5</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Dunn, G. P., Old, L. J., and Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360. doi: 10.1146/annurev.immunol.22.012703.104803</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;text-align:left;
mso-outline-level:2;mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >6</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Bruttel, V. S., and Wischhusen, J. (2014). Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape?. Front. Immunol. 5, 360. doi: 10.3389/fimmu.2014.00360</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >7</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Maccalli, C., Volonte, A., Cimminiello, C., and Parmiani, G. (2014). Immunology of cancer stem cells in solid tumours. A. Rev. Eur. J. Cancer 50 (3), 649–655. doi: 10.1016/j.ejca.2013.11.014</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >8</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Wu, A., Wei, J., Kong, L. Y., Wang, Y., Priebe, W., and Qiao, W. (2010). Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro. Oncol. 12 (11), 1113–1125. doi: 10.1093/neuonc/noq082</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >4</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >9</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Zhou, W., Ke, S. Q., Huang, Z., Flavahan, W., Fang, X., and Paul, J. (2015). Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 17 (2), 170–182. doi: 10.1038/ncb3090</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Jinushi, M., Baghdadi, M., Chiba, S., and Yoshiyama, H. (2012). Regulation of cancer stem cell activities by tumor-associated macrophages. Am. J. Cancer Res. 2 (5), 529–539.</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Yang, J., Liao, D., Chen, C., Liu, Y., Chuang, T. H., and Xiang, R. (2013). Tumorassociated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem. Cells 31 (2), 248–258. doi: 10.1002/stem.1281</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Wynn, T. A., Chawla, A., and Pollard, J. W. (2013). Macrophage biology in development, homeostasis and disease. Nat. 496 (7446), 445–455. doi: 10.1038/nature12034</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Noy, R., and Pollard, J. W. (2014). Tumor-associated macrophages: from mechanisms to therapy. Immun. 41 (1), 49–61. doi: 10.1016/j.immuni.2014.06.010</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >4</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Sarkar, S., Doring, A., Zemp, F. J., Silva, C., Lun, X., and Wang, X. (2014). Therapeutic activation of macrophages and microglia to suppress brain tumorinitiating cells. Nat. Neurosci. 17 (1), 46</span><span style="mso-spacerun:'yes';font-family:微软雅黑;font-size:9.0000pt;
mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >–</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >55. doi: 10.1038/nn.3597</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >5</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Plaks, V., Kong, N., and Werb, Z. (2015). The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. Cell Stem. Cell 16 (3), 225–238. doi: 10.1016/j.stem.2015.02.015</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >6</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >De la Fuente Lopez, M., Landskron, G., Parada, D., Dubois-Camacho, K., Simian, D., and Martinez, M. (2018). The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumorassociated macrophage markers in colorectal cancer. Tumour Biol. 40 (11), 1010428318810059. doi: 10.1177/1010428318810059</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >7</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Palomino, D. C., and Marti, L. C. (2015). Chemokines and immunity. Einstein (Sao Paulo) 13 (3), 469–473. doi: 10.1590/S1679-45082015RB3438</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >8</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Cheng, W. L., Wang, C. S., Huang, Y. H., Tsai, M. M., Liang, Y., and Lin, K. H. (2011). Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann. Oncol. 22 (10), 2267–2276. doi: 10.1093/annonc/mdq739</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >5</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >9</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Kawanishi, H., Matsui, Y., Ito, M., Watanabe, J., Takahashi, T., and Nishizawa, &nbsp;K. (2008). Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder can</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >6</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >0</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Miyake, M., Hori, S., Morizawa, Y., Tatsumi, Y., Nakai, Y., and Anai, S. (2016). CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer. Neoplasia 18 (10), 636–646. doi: 10.1016/j.neo.2016.08.002</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >6</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >1</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Zou, A., Lambert, D., Yeh, H., Yasukawa, K., Behbod, F., and Fan, F. (2014). Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-beta signaling proteins. BMC Cancer 14, 781. doi: 10.1186/1471-2407-14-781</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:5.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >6</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >2</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., and Morris, P.&nbsp;G. (2012). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150 (1), 165–178. doi: 10.1016/j.cell.2012.04.042</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p><p class=MsoNormal  style="margin-bottom:6.0000pt;mso-pagination:widow-orphan;mso-outline-level:2;
mso-line-height-alt:12pt;background:rgb(255,255,255);" ><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >【</font><font face="微软雅黑" >6</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >3</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><font face="微软雅黑" >】</font></span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" >Hsu, Y. L., Chen, Y. J., Chang, W. A., Jian, S. F., Fan, H. L., and Wang, J. Y. (2018). Interaction between tumor-associated dendritic cells and colon cancer cells contributes to tumor progression via CXCL1. Int. J. Mol. Sci. 19 (8), 1–17. doi: 10.3390/ijms19082427</span><span style="mso-spacerun:'yes';font-family:微软雅黑;mso-bidi-font-family:'Times New Roman';
font-size:9.0000pt;mso-font-kerning:1.0000pt;" ><o:p></o:p></span></p></div><!--EndFragment--></body></html>